InterPAD - DETAILS

nevirapine, 129618-40-2, Viramune, BI-RG-587, Nevirapine anhydrous, 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, NVP, BIRG 0587, BIRG587, Viramune XR, 11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one, Nevirapine, anhydrous, 11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6-ONE, Nevirapine teva, BI-RG 587, BIRG-0587, BIRG-587, CHEMBL57, 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one, 11-CYCLOPROPYL-4-METHYL-5H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6(11H)-ONE, MFCD00866928, NEV, NSC-641530, 99DK7FVK1H, 6H-Dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl-, MLS000084585, DTXSID7031797, CHEBI:63613, NSC641530, NCGC00065890-02, SMR000048458, DTXCID9010787, Viramune(TM), Viramune (TN), 2-cyclopropyl-7-methyl-2,4,9,15-tetraazatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3,5,7,12,14-hexaen-10-one, CAS-129618-40-2, HSDB 7164, Nevirapine & CD4-IgG, Nevirapine & PRO 140, UNII-99DK7FVK1H, NSC 641530, Nevirapine (JAN/USP/INN), Nevirapine), 11-cyclopropyl-4-methyl-5H-dipyrido[[?],[?]][1,4]diazepin-6-one, BIRG 587, NON-NUCLEOSIDE RT INHIBITOR NEVIRAPINE, Viramune IR, 1vrt, 2hny, Nevirapine,(S), Nevirapine [USAN:USP:INN:BAN], BI-RG-587 & CD4-IgG, 6H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6-ONE, 11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-, Nevirapinum anhydrous, Nevirapine (Viramune), Nevirapine (anhydrous), NEVIRAPINE [MI], Opera_ID_934, NEVIRAPINE [INN], NEVIRAPINE [JAN], NEVIRAPINE [HSDB], NEVIRAPINE [USAN], NEVIRAPINE [VANDF], NEVIRAPINE [MART.], SCHEMBL3318, NEVIRAPINE [WHO-DD], MLS000759409, MLS001055309, MLS001201730, MLS001424058, MLS006011423, BIDD:GT0326, NEVIRAPINE [EMA EPAR], BDBM1434, BIRG0587, NEVIRAPINE [ORANGE BOOK], GTPL12676, NEVIRAPINE [EP MONOGRAPH], NEVIRAPINE [USP IMPURITY], Nevirapine for peak identification, HMS2051J09, HMS2231O23, HMS3264D21, HMS3371E03, HMS3393J09, HMS3655I08, HMS3715B10, NEVIRAPINE [USP MONOGRAPH], Pharmakon1600-01503842, ALBB-027264, BCP05587, Tox21 110982, Tox21_110982, Tox21_200770, AC-643, AC1280, BBL010768, NSC759902, STK580320, NEVIRAPINE ANHYDROUS [USP-RS], NEVIRAPINE ANHYDROUS [WHO-IP], AKOS005504351, Tox21_110982_1, AB07544, CCG-100939, DB00238, KS-5019, NC00189, NSC-759902, NCGC00065890-03, NCGC00065890-04, NCGC00065890-05, NCGC00065890-07, NCGC00065890-14, NCGC00258324-01, 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one & PRO 140 (Anti-CCR5 monoclonal antibody), 2-cyclopropyl-7-methyl-2,4,9,15-tetrazatricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-10-one, HY-10570, N11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e]-[1,4]diazepin-6-one & CD4-immunoadhesin, Nevirapine 100 microg/mL in Acetonitrile, SY009679, BI-RG 587;NSC 641530;NVP, DB-041930, FT-0607215, FT-0672686, N0922, NEVIRAPINUM ANHYDROUS [WHO-IP LATIN], NS00004959, S1742, SW197569-2, C07263, D00435, EN300-119500, AB00393001-13, AB00393001-15, AB00393001_16, AB00393001_17, Q263713, F2173-0607, Z1521553473, BI-RG-587; BIRG 0587; BIRG587; HSDB 7164; NSC 641530; NVP, Nevirapine (anhydrous), European Pharmacopoeia (EP) Reference Standard, Nevirapine anhydrous, United States Pharmacopeia (USP) Reference Standard, Nevirapine, Pharmaceutical Secondary Standard; Certified Reference Material, 11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido-[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b :2',3'-e][1,4 ]diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2 ,3 -e][1,4]diazepin-6-one, 11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2', 3'-e][1,4]diazepin-6-one, 6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl-, Nevirapine for peak identification, European Pharmacopoeia (EP) Reference Standard, 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2 inverted exclamation mark ,3 inverted exclamation mark -e][1,4]diazepin-6-one, 2-cyclopropyl-7-methyl-2,4,9,15-tetraazatricyclo[9.4.0.0,3,8]pentadeca-1(15),3(8),4,6,11,13-hexaen-10-one, 2-cyclopropyl-7-methyl-2,4,9,15-tetraazatricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3,5,7,11,13-hexaen-10-one

Name	Nevirapine
PubChem CID	4463
Molecular Weight	266.30g/mol
Synonyms	nevirapine, 129618-40-2, Viramune, BI-RG-587, Nevirapine anhydrous, 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, NVP, BIRG 0587, BIRG587, Viramune XR, 11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one, Nevirapine, anhydrous, 11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6-ONE, Nevirapine teva, BI-RG 587, BIRG-0587, BIRG-587, CHEMBL57, 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one, 11-CYCLOPROPYL-4-METHYL-5H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6(11H)-ONE, MFCD00866928, NEV, NSC-641530, 99DK7FVK1H, 6H-Dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl-, MLS000084585, DTXSID7031797, CHEBI:63613, NSC641530, NCGC00065890-02, SMR000048458, DTXCID9010787, Viramune(TM), Viramune (TN), 2-cyclopropyl-7-methyl-2,4,9,15-tetraazatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3,5,7,12,14-hexaen-10-one, CAS-129618-40-2, HSDB 7164, Nevirapine & CD4-IgG, Nevirapine & PRO 140, UNII-99DK7FVK1H, NSC 641530, Nevirapine (JAN/USP/INN), Nevirapine), 11-cyclopropyl-4-methyl-5H-dipyrido[[?],[?]][1,4]diazepin-6-one, BIRG 587, NON-NUCLEOSIDE RT INHIBITOR NEVIRAPINE, Viramune IR, 1vrt, 2hny, Nevirapine,(S), Nevirapine [USAN:USP:INN:BAN], BI-RG-587 & CD4-IgG, 6H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6-ONE, 11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-, Nevirapinum anhydrous, Nevirapine (Viramune), Nevirapine (anhydrous), NEVIRAPINE [MI], Opera_ID_934, NEVIRAPINE [INN], NEVIRAPINE [JAN], NEVIRAPINE [HSDB], NEVIRAPINE [USAN], NEVIRAPINE [VANDF], NEVIRAPINE [MART.], SCHEMBL3318, NEVIRAPINE [WHO-DD], MLS000759409, MLS001055309, MLS001201730, MLS001424058, MLS006011423, BIDD:GT0326, NEVIRAPINE [EMA EPAR], BDBM1434, BIRG0587, NEVIRAPINE [ORANGE BOOK], GTPL12676, NEVIRAPINE [EP MONOGRAPH], NEVIRAPINE [USP IMPURITY], Nevirapine for peak identification, HMS2051J09, HMS2231O23, HMS3264D21, HMS3371E03, HMS3393J09, HMS3655I08, HMS3715B10, NEVIRAPINE [USP MONOGRAPH], Pharmakon1600-01503842, ALBB-027264, BCP05587, Tox21 110982, Tox21_110982, Tox21_200770, AC-643, AC1280, BBL010768, NSC759902, STK580320, NEVIRAPINE ANHYDROUS [USP-RS], NEVIRAPINE ANHYDROUS [WHO-IP], AKOS005504351, Tox21_110982_1, AB07544, CCG-100939, DB00238, KS-5019, NC00189, NSC-759902, NCGC00065890-03, NCGC00065890-04, NCGC00065890-05, NCGC00065890-07, NCGC00065890-14, NCGC00258324-01, 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one & PRO 140 (Anti-CCR5 monoclonal antibody), 2-cyclopropyl-7-methyl-2,4,9,15-tetrazatricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-10-one, HY-10570, N11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e]-[1,4]diazepin-6-one & CD4-immunoadhesin, Nevirapine 100 microg/mL in Acetonitrile, SY009679, BI-RG 587;NSC 641530;NVP, DB-041930, FT-0607215, FT-0672686, N0922, NEVIRAPINUM ANHYDROUS [WHO-IP LATIN], NS00004959, S1742, SW197569-2, C07263, D00435, EN300-119500, AB00393001-13, AB00393001-15, AB00393001_16, AB00393001_17, Q263713, F2173-0607, Z1521553473, BI-RG-587; BIRG 0587; BIRG587; HSDB 7164; NSC 641530; NVP, Nevirapine (anhydrous), European Pharmacopoeia (EP) Reference Standard, Nevirapine anhydrous, United States Pharmacopeia (USP) Reference Standard, Nevirapine, Pharmaceutical Secondary Standard; Certified Reference Material, 11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido-[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b :2',3'-e][1,4 ]diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2 ,3 -e][1,4]diazepin-6-one, 11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2', 3'-e][1,4]diazepin-6-one, 6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl-, Nevirapine for peak identification, European Pharmacopoeia (EP) Reference Standard, 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2 inverted exclamation mark ,3 inverted exclamation mark -e][1,4]diazepin-6-one, 2-cyclopropyl-7-methyl-2,4,9,15-tetraazatricyclo[9.4.0.0,3,8]pentadeca-1(15),3(8),4,6,11,13-hexaen-10-one, 2-cyclopropyl-7-methyl-2,4,9,15-tetraazatricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3,5,7,11,13-hexaen-10-one
Drug Type	Small molecule
Formula	C₁₅H₁₄N₄O
SMILES	CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4
InChI	1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20)
InChIKey	NQDJXKOVJZTUJA-UHFFFAOYSA-N
CAS Number	129618-40-2
ChEMBL ID	CHEMBL57
ChEBI ID	CHEBI:63613
TTD ID	D0O2EM
Drug Bank ID	DB00238
KEGG ID	C07263
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Artesunate, Nevirapine
Partner Name	Artesunate
Result	Coadministration with nevirapine may decrease the peak plasma concentration (Cmax) and systemic exposure (AUC) of dihydroartemisinin (DHA), an active metabolite of artesunate. The mechanism is unknown. Reduced efficacy of artesunate may occur.